News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Results>HENGRUI PHARMA 2025 NP Surges 21.7% to RMB7.711B; Final Div. RMB20 Cents
HENGRUI PHARMA (01276.HK) has announced its annual results for the year ended December 2025.The company's turnover rose by 13% YoY to RMB31.629 billion, while net profit surged...
Reset
Send
The window will close in 5 seconds
<Results>HENGRUI PHARMA 2025 NP Surges 21.7% to RMB7.711B; Final Div. RMB20 Cents
Close
Recommend
6
Positive
10
Negative
7
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

HENGRUI PHARMA (01276.HK)  -2.500 (-4.248%)    Short selling $30.98M; Ratio 20.027%   has announced its annual results for the year ended December 2025.

Dividend History
Announce DateEventParticular
2025/10/273rd QuarterlyNo Dividend
2025/08/20InterimNo Dividend

The company's turnover rose by 13% YoY to RMB31.629 billion, while net profit surged by 21.7% YoY to RMB7.711 billion, with EPS at RMB1.19. A final dividend of RMB2 per 10 shares was declared.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.)

Related News Citi Lists Latest H Shrs Buy Top Picks (Table)
Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.